Tianjin Medical University Cancer Institute and Hospital is the birthplace of oncology in China. It has developed into one of the largest cancer centers in China.

During the past decade, Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital" #1 collaborator was "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 1 trials as a collaborator, "Harbin Medical University" with 1 trials as a collaborator, "Hebei Medical University Fourth Hospital" with 1 trials as a collaborator, "Liaoning Tumor Hospital & Institute" with 1 trials as a collaborator and "Ruijin Hospital" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital" are "Esophageal Squamous Cell Carcinoma" (2 trials), "Adenocarcinoma of Esophagogastric Junction" (1 trials), "Esophageal Cancer" (1 trials), "Neoadjuvant Chemotherapy" (1 trials) and "Pembrolizumab" (1 trials). Many other conditions were trialed in "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital" in a lesser frequency.

Most popular intervention types in "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital" are "Drug" (3 trials), "Biological" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab Injection [Keytruda]" (2 trials), "Cisplatin" (1 trials), "Paclitaxel" (1 trials), "Pembrolizumab" (1 trials) and "intraoperative nerve monitoring" (1 trials). Other intervention names were less common.

The vast majority of trials in "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".